Related references
Note: Only part of the references are listed.Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma
Jose Lopez et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant therapy for localized and locally advanced renal cell carcinoma
Ahmet Bindayi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B. Schaaf et al.
CELL DEATH & DISEASE (2018)
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
Aly-Khan A. Lalani et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma
Leonardo D. Borregales et al.
THERAPEUTIC ADVANCES IN UROLOGY (2016)
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals
Wenbin Song et al.
ONCOTARGET (2015)
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Pierre Bigot et al.
WORLD JOURNAL OF UROLOGY (2014)
Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma
David E. Gyorki et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension: a multi-institutional retrospective study in Japan
[Anonymous]
BMC CANCER (2013)
Natural history of untreated renal cell carcinoma with venous tumor thrombus
Adam C. Reese et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus
Nicholas G. Cost et al.
EUROPEAN UROLOGY (2011)
Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma
Brian F. Chapin et al.
EUROPEAN UROLOGY (2011)
Contemporary Management of Renal Tumors With Venous Tumor Thrombus
Frederic Pouliot et al.
JOURNAL OF UROLOGY (2010)
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size?
Jordan M. Kurta et al.
BJU INTERNATIONAL (2009)
Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma
Gregoire Robert et al.
EUROPEAN UROLOGY (2009)
Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma
Hanne Krogh Jensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
ML Blute et al.
BJU INTERNATIONAL (2004)